Al-Ghamrawy:
-Cooperation with China opens new horizons for pharmaceutical and biological manufacturing and enhances export expansion
-We are working to create an innovative environment that supports scientific research and innovation in line with the highest international standards
Chen Xiaoqing: The Egyptian market is a strategic gateway for regional manufacturing and export
Dr. Ali Al-Ghamrawy held an expanded meeting with Mr. Chen Xiaoqing, CEO of Shenzhen Ruiyan Biotechnology. The meeting comes within the framework of the Authority’s efforts to enhance investment and develop pharmaceutical and medical industries in Egypt, and to explore opportunities for joint cooperation in line with the state’s strategy to support the health sector and strengthen national capabilities.
The meeting focused on the potential establishment of a manufacturing facility for certain biological products within one of Egypt’s free industrial zones aiming to supporting local production and exporting to regional and international markets. It also explored investment opportunities in biotechnology, pharmaceuticals, and medical technologies, contributing to stronger supply chains and enhanced competitiveness of Egyptian products. Also reviewed the regulatory frameworks, registration pathways, and approval processes overseen by the EDA to ensure compliance with national and international standards.
Dr. Al-Ghamrawy emphasized the importance of strengthening cooperation with leading international companies to achieve pharmaceutical security, enhance self-sufficiency, and elevate Egypt’s position as a regional hub for the manufacture and export of high-quality pharmaceutical products, highlighting the EDA’s commitment to providing full technical and regulatory support to investors to ensure the success of joint projects.
He noted that the EDA is working to strengthen the ecosystem of innovation and sustainable development in Egypt’s pharmaceutical sector by encouraging scientific research and adopting the latest manufacturing technologies and biological products, ensuring product quality and safety, and seeking to create an integrated environment that combines quality, innovation, and sustainability across pharmaceutical technology industries.
Shenzhen Ruiyan welcomed the cooperation with the EDA, affirming its commitment to building a strategic partnership that supports technology transfer, localization of expertise within the Egyptian market, and enhancing export opportunities to regional and global markets.
The company expressed its appreciation for the EDA’s pivotal role in regulating and supporting the pharmaceutical technology sectors, commending the efforts made to facilitate regulatory procedures, stimulate investment, and provide a supportive environment that ensures the quality, efficacy, and safety of pharmaceutical products.